Evidence map›Paper›PMID 38573132›Full record

ArticleFuture oncology (London, England)2024

Patient engagement in designing and publishing research in prostate cancer: a scoping review.

Linda Sutton, Matthew Labriola, Thomas Bognanno, Shelby Moneer, Jennifer Ghith, Gustavo Rodriguez, Latorya Moore, Obaro Evuarherhe, Alicia K Morgans

Open access · hybridAbstract readScoping Review
In one paragraph

Article in Future oncology (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Linda SuttonDuke Cancer Institute, Durham, NC 27710, USA.ORCID 0000-0002-1576-4113
Matthew LabriolaDuke Cancer Institute, Durham, NC 27710, USA.
Thomas BognannoCreating Healthier Communities, Alexandria, VA 22314, USA.
Shelby MoneerZERO - The End of Prostate Cancer, Alexandria, VA 22314, USA.
Jennifer GhithPfizer Oncology, Royersford, PA 19426, USA.
Gustavo RodriguezPfizer Oncology, New York, NY 10001, USA.
Latorya MooreDuke Cancer Institute, Durham, NC 27710, USA.
Obaro EvuarherheOxford PharmaGenesis, Oxford, OX1 1BN, UK.
Alicia K MorgansDana-Farber Cancer Institute, Boston, MA 02215, USA.
Duke Medical Center · USPfizer (United States) · USDana-Farber Cancer Institute · USOxford Instruments (United Kingdom) · GBProstate Cancer Foundation · US

Funding

Pfizer
6 · The paper itself

Abstract

Patients with cancer have the unique ability of being able to offer valuable insights into how cancer therapeutics may impact the overall patient experience and improve clinical outcomes. Patient engagement could therefore contribute to tailoring treatment strategies and research design according to patient needs. This study evaluated patient engagement in prostate cancer research by identifying patient input in the prostate cancer literature. We performed a keyword cluster analysis of articles from multiple databases and congresses in which patients provided input on disease management or were involved in study design, manuscript authorship or presentation of results (patient voice). In total, 112 studies were included. Patients were involved in the design of 11 studies and were credited as authors in four studies. This review suggests a lack of meaningful patient involvement in prostate cancer research and publications.

Indexed as

Patient ParticipationProstatic NeoplasmsResearch DesignBiomedical ResearchHumansMalePublishingpatient authorshippatient engagementpatient involvementpatient participationpatient-reported outcomesprostate cancerprostate neoplasm

Identifiers

PMID38573132
PMCPMC11572254
OpenAlexW4393949915

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.